Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04075825 · ClinicalTrials.gov registry record · Phase 3

Long-term Follow-up Study With Darvadstrocel in the Treatment of Complex Perianal Fistula

A Phase 3 study, sponsored by Takeda.

Completed
Registry status
Phase 3
Development phase
150
Enrollment target

NCT04075825 is a Phase 3 study that has completed, run by Takeda. The registered enrollment target is 150 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04075825, a Phase 3 study, has completed, sponsored by Takeda.

COMPLETED
Registry status
Phase 3
Development phase
150 participants
Enrollment target

Study Summary

The main aim is to follow-up on long term side effect and symptom improvement of Darvadstrocel in the treatment of complex perianal fistula in adults. Participants will not receive any drug in this study.

Interventions

  • OTHER Placebo
  • BIOLOGICAL Darvadstrocel

Trial Details

FieldValue
Enrollment Target 150 participants
Start Date 2019-11-05
Est. Completion 2024-04-02
Phase Phase 3

Sponsor

Takeda

408 total trials

What the Registry Record Tells You About NCT04075825

The ClinicalTrials.gov registry entry for NCT04075825 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Takeda, which has 408 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.

NCT04075825 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT04075825 about?

NCT04075825 is a clinical study titled "Long-term Follow-up Study With Darvadstrocel in the Treatment of Complex Perianal Fistula". The main aim is to follow-up on long term side effect and symptom improvement of Darvadstrocel in the treatment of complex perianal fistula in adults. Participants will not receive any drug in this study.

What is the current status of trial NCT04075825?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 150 participants. The study started on 2019-11-05. Estimated completion is 2024-04-02.

What interventions are being tested in trial NCT04075825?

The interventions under investigation include: Placebo (OTHER), Darvadstrocel (BIOLOGICAL).

Who is sponsoring clinical trial NCT04075825?

This trial is sponsored by Takeda, which has 408 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.